Corton Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Corton Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,424	Closed	-$570K	–	286
2025 Q2	$570K	Buy	+14,424	New	+$472K	0.66%	8
2024 Q2	–	Sell	-10,631	Closed	-$461K	–	619
2024 Q1	$461K	Sell	10,631 -845	-7%	-$40.3K	0.17%	155
2023 Q4	$581K	Buy	11,476 +2,581	+29%	+$124K	0.18%	136
2023 Q3	$403K	Buy	8,895 +1,966	+28%	+$81.1K	0.2%	139
2023 Q2	$284K	Sell	6,929 -2,111	-23%	-$81.1K	0.13%	228
2023 Q1	$323K	Sell	9,040 -3,598	-28%	-$135K	0.22%	131
2022 Q4	$477K	Buy	12,638 +3,215	+34%	+$135K	0.39%	64
2022 Q3	$417K	Buy	9,423 +1,025	+12%	+$43.2K	0.51%	59
2022 Q2	$311K	Sell	8,398 -411	-5%	-$15.5K	0.29%	139
2022 Q1	$326K	Buy	+8,809	New	+$288K	0.14%	207

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's IONS Position: Q3 2025 in Review

Corton Capital sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 14,424 shares — an estimated $570K sold.

Corton Capital first reported a position in IONS in Q1 2022 and held it in 10 quarters. The position peaked at $581K in Q4 2023. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

Corton Capital reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Corton Capital sold 14,424 Ionis Pharmaceuticals shares in Q3 2025, an estimated $570K.
Corton Capital first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 10 quarters.
Corton Capital's Ionis Pharmaceuticals position peaked at $581K in Q4 2023.
435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.